Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
Agilent (NYSE: A) awarded Boehringer Ingelheim the inaugural 2025 Instrument Trade‑In Impact Award for leading Agilent partners in sustainable trade‑in activity. In 2025 Boehringer Ingelheim diverted 6,600 kg of instrument waste from landfill via reuse, refurbishment, or proper recycling.
The award recognizes measurable progress toward a circular economy and supports Agilent’s programs to reduce laboratory waste and extend instrument lifecycles.
Agilent (NYSE: A) announced FDA approval of PD-L1 IHC 22C3 pharmDx, Code SK006 as the only FDA‑approved companion diagnostic to identify first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC) patients whose tumors express PD‑L1 and may be eligible for KEYTRUDA.
This marks the seventh FDA companion diagnostic indication for the test and enables PD‑L1 assessment at diagnosis to support first‑line treatment decisions; Agilent reported $6.95 billion revenue in fiscal 2025.
Agilent (NYSE: A) will showcase next‑generation automated workflow solutions at SLAS2026 in Boston, Feb 7–11, 2026. The company will demo integrated imaging, robotics partnerships, AI‑driven CrossLab Connect enhancements, a new Cytation imaging platform preview, ProteoAnalyzer Software Security Module, and updated Bravo liquid‑handling protocols.
The exhibits include multi‑vendor integrations with ABB Robotics, HighRes Biosolutions, Biosero, and Unite Labs, two exhibitor tutorials, a spotlight presentation, and participation in conference panels.
Agilent (NYSE: A) will report first-quarter fiscal 2026 results after market close on Feb. 25, 2026 and will host a listen-only conference call/webcast at 1:30 p.m. PST the same day.
A recording will be available on the company's investor relations site for 90 days. Agilent reported $6.95 billion revenue in fiscal 2025 and employs about 18,000 people worldwide.
Agilent (NYSE: A) launched the Agilent S540MD Slide Scanner System on January 23, 2026, a whole slide imaging scanner for high-volume digital pathology in key European markets. Engineered for speed and scalability, the system holds up to 540 slides, supports continuous loading, standard rack compatibility, automated scanning modes, and AI-assisted tissue detection. The scanner is an Agilent-branded version of the Hamamatsu NanoZoomer S540MD and will be available as IVD initially in Germany, France, Belgium, Spain, Austria, Luxembourg, Italy, the UK, and Switzerland, with further European expansion and milestones planned for 2026.
Agilent (NYSE: A) announced that CEO Padraig McDonnell and CFO Adam Elinoff will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 13, 2026, 9:00–9:40 a.m. PST. A live audio webcast and replay will be available via Agilent’s investor relations website.
Agilent reported $6.95 billion in revenue for fiscal year 2025 and employs approximately 18,000 people worldwide. The presentation likely will review recent performance and strategic priorities; investors can access the webcast and contact investor relations for more information.
Agilent (NYSE: A) released a 21 CFR Part 11 compliance software upgrade for the xCELLigence RTCA eSight system on December 1, 2025. The software adds a compliance license and enhanced security features—secure user authentication, electronic signatures, and complete audit trails—enabling deployment in GMP-regulated manufacturing and quality control as well as drug discovery labs.
The upgrade is positioned to support continuity from early research to production, improve audit readiness, and simplify regulatory submissions while maintaining workflow efficiency and data quality.
Agilent (NYSE: A) reported Q4 FY2025 revenue $1.86B, up 9.4% reported and up 7.2% on a core basis versus Q4 2024, with GAAP EPS of $1.53 (up 25% YoY) and non-GAAP EPS of $1.59 (up 9% YoY). Full FY2025 revenue was $6.95B, up 6.7% reported; FY2025 GAAP EPS was $4.57 and non-GAAP EPS was $5.59. Management provided FY2026 guidance of $7.3B–$7.4B revenue (up 5%–7% reported) and non-GAAP EPS $5.86–$6.00; Q1 FY2026 revenue guidance is $1.79B–$1.82B with non-GAAP EPS $1.35–$1.38.
Agilent (NYSE: A) announced a quarterly cash dividend of 25.5 cents per share. The dividend is payable on Jan. 28, 2026 to shareholders of record at the close of business on Jan. 6, 2026. The company said timing and amounts of future dividends remain subject to the board of directors’ determination and approval.
Agilent reported $6.51 billion in revenue for fiscal year 2024 and employs approximately 18,000 people worldwide. The release includes customary forward-looking statement language about risks and uncertainties related to the dividend program.
Agilent (NYSE: A) will participate in Citi’s 2025 Global Healthcare Conference on Dec. 4, 2025. Chief Enterprise Transformation Officer Tom Callihan and Head of Investor Relations Tejas Savant will take part in a fireside chat from 9:00 to 9:45 a.m. EDT in Miami.
A live audio webcast and replay will be available on Agilent’s investor relations website. Agilent reported $6.51 billion revenue in fiscal year 2024 and employs approximately 18,000 people worldwide.